Never judge a book by its cover –we know it, but we all do it. When working on a document I try to keep titles short and to the point, particularly scientific manuscripts. From my own experience searching through reams of references I know that titles longer than a single line are a pain. Research published recently seems to underline my own observations. Apparently, you can predict the popularity of a scientific paper from the length of its title [1]. It turns out that brevity can earn a paper more attention. More correctly, analysis shows that articles with shorter titles tend to get cited more often than those with longer headers.
For certain, titles are the first thing that readers see, and yet they are the aspect of your work that is given the least attention. Yes, creating a title can take you just a few seconds, but does that investment of time reflect the potential impact it could have?
Titles directly influence the number of people who end up reading your work. People use online databases to search for relevant materials. That’s why, if you want your article to appear in search results, you should ensure that its title is a good reflection of what you are reporting and that it attracts the right audience. The words you use will determine whether your audience will find your work, and when they do, whether they chose to simply overlook it or explore it further.
I first became interested in the influence titles could have when I was writing up my PhD. I wrote myself a list of key points to remember when creating titles. I have updated it several times over the years. We converted the list to a guide on how to write brilliant titles when Niche started publishing its Insider’s Insights a few years ago [2]. There are some great short titles. For example, The Lancet published an article entitled ‘Myopia’ and another called ‘Measles’. Of my own work my favourite is “Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’ [3]”. I always thought it to be rather snappy. However, it has been cited less often than “Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes” published a year later [4]. At the time the editor of the “Sweet Pee” article suggested that our title was “Pithy” but I reassured him that the mild humour would draw attention to the work – it seems I was wrong. Clearly, our efforts to understand factors that influence citation rates are fraught with challenges but you want to give your work every chance of being recognised (BTW – our Insider’s Insight on understanding bibliometrics is available for downloading [5].
Not everything points to the same conclusions about brevity in titles. A 2010 study, for instance, suggests that longer titles lead to a higher citation rate, but it only reviewed a sample of 50 papers published in medical journals. A 2011 study, on the other hand, found no clear relationship between title length and citation numbers. It reviewed titles and metrics for 2,172 papers published in PLOS journals. Check out the Insider’s Insights then you decide.
Finding the best vehicle in which to publish your research findings is a perennial challenge.
We all need heroes - people who can champion our cause - helping the world to understand our rationale
I am continually reminded that I must work toward better relationships with my sons than the one I had with my dad.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
ive years ago I was lucky enough to be involved in a project that resulted in publications
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
The internet was set alight last week on the issue of differences in the approach to emails adopted by men and women.
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Searching the literature can take various forms, ranging from a quick scan of recent publications
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Did you miss our Insider's Insight into understanding the complex world of bibliometrics [1]?
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Our team are exploring different and novel ways for young people to enter the pharmaceutical industry.
Scientific knowledge should be accessible to all and if you are those communicating science
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
